[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MD430C2 - Method for human leucocytar interferone preparation - Google Patents

Method for human leucocytar interferone preparation

Info

Publication number
MD430C2
MD430C2 MD95-0076A MD950076A MD430C2 MD 430 C2 MD430 C2 MD 430C2 MD 950076 A MD950076 A MD 950076A MD 430 C2 MD430 C2 MD 430C2
Authority
MD
Moldova
Prior art keywords
pst
pbr
leucocytar
interferone
preparation
Prior art date
Application number
MD95-0076A
Other languages
Romanian (ro)
Russian (ru)
Inventor
Van Norman Goeddel David
Pestka Sidney
Original Assignee
F.Hoffmann-La Roche Ag
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag, Genentech, Inc. filed Critical F.Hoffmann-La Roche Ag
Publication of MD430C2 publication Critical patent/MD430C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Application field: genetic engineering, leucocytar interferone preparation. The summary of the invention: the method comprises the DNA sequence detection and isolation and recombinant molecules construction, coding the polypeptide which possesses the immunologic and biologic activity of HIFN-α. there are obtained recombinant plasmide DNA, containing the Z-pBR 322 (Pst)HCIF-4c, Z-pBR 322 (Pst), HIF-2h, Z-pBR 322 (Pst) HcIF-SN-35, Z-pBR 322 (Pst) Hc1F-SN-42, Z-pKT287 (Pst) Hc1F-2h-AH6 DNA sequence as well as the sequences which are hybridizated with the mentioned insertions.
MD95-0076A 1980-07-01 1994-12-30 Method for human leucocytar interferone preparation MD430C2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16498680A 1980-07-01 1980-07-01
US18490980A 1980-09-08 1980-09-08
US20557880A 1980-11-10 1980-11-10
US06/256,204 US6610830B1 (en) 1980-07-01 1981-04-21 Microbial production of mature human leukocyte interferons

Publications (1)

Publication Number Publication Date
MD430C2 true MD430C2 (en) 1996-06-30

Family

ID=27389083

Family Applications (1)

Application Number Title Priority Date Filing Date
MD95-0076A MD430C2 (en) 1980-07-01 1994-12-30 Method for human leucocytar interferone preparation

Country Status (6)

Country Link
US (2) US6610830B1 (en)
KR (1) KR860001558B1 (en)
CA (1) CA1341583C (en)
GE (1) GEP20074163B (en)
MD (1) MD430C2 (en)
ZW (1) ZW14781A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835557B1 (en) * 1980-01-08 2004-12-28 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human interferon-like polypeptides
FR2686899B1 (en) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
CA2747325A1 (en) * 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US7959910B2 (en) 2000-07-31 2011-06-14 Biolex Therapeutics, Inc. C-terminally truncated interferon alpha variants
AU2888602A (en) * 2000-11-03 2002-05-15 Pbl Biomedical Lab Interferons, uses and compositions related thereto
FR2822845B1 (en) * 2001-03-30 2003-12-12 Genodyssee NOVEL POLYNUCLEOTIDES COMPRISING FUNCTIONAL SNP-LIKE POLYMORPHISMS IN THE NUCLEOTIDE SEQUENCE OF THE IFN-ALPHA-21 GENE AS WELL AS NEW POLYPEPTIDES ENCODED BY THESE POLYNUCLEOTIDES AND THEIR THERAPEUTIC USES
AU2002346686A1 (en) * 2001-12-07 2003-06-23 Intermune, Inc. Compositions and method for treating hepatitis virus infection
KR101271635B1 (en) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 Albumin fusion proteins
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
KR20040020817A (en) * 2002-08-31 2004-03-09 씨제이 주식회사 Glycosylated human interferon alpha isoform
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US20040219131A1 (en) * 2002-11-18 2004-11-04 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
BR0317752A (en) * 2002-12-26 2005-11-22 Mountain View Pharmaceuticals Polymeric cytokine conjugates, chemokines, growth factors, polypeptide hormones and their antagonists with conserved receptor binding activity
PT1667708E (en) 2002-12-26 2012-09-14 Mountain View Pharmaceuticals Polyethylene glycol conjugates of interferon-beta-1b with enhanced in vitro biological potency
CA2553034A1 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human interferon polypeptides and their uses
WO2005113592A2 (en) * 2004-05-19 2005-12-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US20060024272A1 (en) * 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
WO2006111745A2 (en) * 2005-04-20 2006-10-26 Viragen Incorporated Composition and method for treating viral infection
CN101501068A (en) * 2005-05-18 2009-08-05 马克西根公司 Evolved interferon-alpha polypeptides
KR20080021614A (en) * 2005-05-26 2008-03-07 쉐링 코포레이션 Interferon-IgX Fusion
EP1893229B1 (en) * 2005-06-03 2011-10-19 Ambrx, Inc. Improved human interferon molecules and their uses
US7770595B2 (en) * 2006-04-27 2010-08-10 Sko Flo Industries, Inc. Flow control valve
US8679472B1 (en) 2006-10-05 2014-03-25 Merck, Sharp & Dohme Corp. Crystal of human interferon alpha 2B in complex with zinc
AU2008239595A1 (en) * 2007-04-11 2008-10-23 Pestka Biomedical Laboratories, Inc. Interferons of Rhesus and Cynomolgus origin and uses thereof
NZ580686A (en) 2007-05-02 2012-11-30 Ambrx Inc Modified interferon beta polypeptides and their uses
AU2008279087A1 (en) * 2007-07-25 2009-01-29 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of HCV infection using same
DK2196475T3 (en) * 2007-09-04 2012-09-17 Biosteed Gene Expression Tech Co Ltd Interferon alfa 2a modified with polyethylene glycol, method of synthesis thereof and use thereof
NZ586947A (en) 2008-02-08 2012-11-30 Ambrx Inc Modified leptin polypeptides and their uses
JP5675606B2 (en) 2008-07-08 2015-02-25 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Novel inhibitor of signal transduction transcription factor (STAT) proliferation and activation
WO2012175700A1 (en) 2011-06-23 2012-12-27 Digna Biotech, S. L. Treatment of chronic hepatitis c with ifn-a5 combined with ifn-a2b in a cohort of patients
US8980267B2 (en) 2012-03-03 2015-03-17 Immungene Inc Engineered antibody-interferon mutant fusion molecules
WO2013175487A2 (en) * 2012-03-30 2013-11-28 Krishnan Archana Rajesh Codon optimized sequence for an antiviral protein
CU24554B1 (en) * 2018-05-07 2021-11-04 Ct Inmunologia Molecular FUSION PROTEINS COMPOSED OF INTERLEUKIN 2 MUTEIN AND TYPE 1 INTERFERON

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7811042A (en) 1977-11-08 1979-05-10 Genentech Inc METHOD AND MEANS FOR EXPRESSING MICROBIAL POLYPEPTIDE.
US4411994A (en) 1978-06-08 1983-10-25 The President And Fellows Of Harvard College Protein synthesis
IN150740B (en) * 1978-11-24 1982-12-04 Hoffmann La Roche
US4503035B1 (en) 1978-11-24 1996-03-19 Hoffmann La Roche Protein purification process and product
US4332892A (en) 1979-01-15 1982-06-01 President And Fellows Of Harvard College Protein synthesis
ES479300A1 (en) 1979-04-04 1979-07-01 Cusi Lab An alpha-methyl-4(2'-thienyl-carbonyl)phenyl acetic acid derivative, process for its preparation and its pharmaceutical use.
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4418149A (en) 1980-01-10 1983-11-29 President And Fellows Of Harvard College Fused hybrid gene
US4810645A (en) 1981-08-14 1989-03-07 Hoffmann-La Roche Inc. Microbial production of mature human leukocyte interferon K and L
US4801685A (en) 1981-08-14 1989-01-31 Hoffmann-La Roche Inc. Microbial production of mature human leukocyte interferon K and L

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Shigekazu N. et al. Synthensin E. coli of a polypeptide with human leukocyte interferon activity. Nature, v. 284, March, 1980, p. 316-320. *

Also Published As

Publication number Publication date
US6610830B1 (en) 2003-08-26
GEP20074163B (en) 2007-07-10
CA1341583C (en) 2008-11-18
ZW14781A1 (en) 1982-04-21
KR830006422A (en) 1983-09-24
KR860001558B1 (en) 1986-10-04
US6482613B1 (en) 2002-11-19

Similar Documents

Publication Publication Date Title
MD430C2 (en) Method for human leucocytar interferone preparation
MD431C2 (en) Method for leukocytar interferone preparation
AU4833897A (en) Glial mitogenic factors, their preparation and use
DK288183A (en) PROCEDURE FOR THE PREPARATION OF AN OLIGONUCLEOTIDE THERAPEUTIC AGENT
KR970000808B1 (en) Human proapolipoprotein a-1 expression
MY101972A (en) Primate interleukin - 4
ZA859437B (en) Dna sequence encoding a hirudin-like protein and process for preparing such protein
DK188582A (en) BACILLUS CLONING VECTORS RECOMBINATION DNA MOLECULES BACILLUS VALUES TRANSFORMED THEREOF, AND PROCEDURES FOR EXPRESSION OF PROCESSED DNA SEQUENCES AND PREPARATION OF POLYPEPTIDES CODED THEREOF
ATE182901T1 (en) DNA CODING FOR ANDROGEN RECEPTOR PROTEIN
DE3586697D1 (en) Aktive thymopentin-analoga.
PT84089A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
ES8704207A1 (en) Rhinovirus strain HRV2 polypeptides and DNA molecules encoding them.
JPS615392B2 (en)
FI961202A (en) Grb3-3 gene, its variants and their uses
MX9703364A (en) Peptides capable of binding to the gap protein sh3 domain, nucleotide sequences coding therefor, and preparation and use thereof.
GB9215232D0 (en) Vaccines
GB2171703B (en) Expression-secretion vector for gene expression and protein secretion, recombinant dna including the vector, and method of producing proteins by use of the re
DK0643719T3 (en) Nucleic acid sequences encoding or complementary to nucleic acid sequences encoding interleukin 9 receptor
EP0770137A4 (en) Improvements in production of proteins in host cells
ATE215123T1 (en) OR-1, A WAIS RECEPTOR OF THE NUCLEAR RECEPTOR FAMILY
ES8800353A1 (en) MOLECULAR CLONING OF cDNA FOR HUMAN FACTOR VIIIR (VON WILLEBRAND FACTOR).
ES8605296A1 (en) Recominant factor VIII-R.
WO1990003394A3 (en) New limphokines, dna sequences coding for said limphokines and pharmaceutical compositions containing said limphokines